Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer

CIL during early treatment cycles was independently associated with superior survival in patients with recurrent CC. In the absence of infectious complications, leukopenia may reflect adequate pharmacodynamic drug exposure and host treatment response. It should be interpreted as a post-hoc prognostic indicator, supporting its potential role as a pragmatic surrogate marker of chemotherapy efficacy.